Lysogene SAS raised €16.5 million (US$22.6 million) in a series A round to continue its clinical development of SAF-301, a gene therapy treatment for Sanfilippo syndrome type A, a rare neurodegenerative disorder arising from impaired breakdown of the cell surface and extracellular matrix component heparan sulfate.